Transdermal iontophoresis of hydromorphone across hairless rat skin in vitro

Pharmaceutical Development and Technology

Volumn 14, Issue 1, 2009, Pages 109-118

  Kumar, Maansi G ^a   Lin, Senshang ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

Flux; Hydromorphone; Iontophoresis; Pain; Skin; Transdermal

Indexed keywords

BUFFER; HYDROMORPHONE; ION;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG PENETRATION; ELECTRIC CURRENT; ELECTRODE; HAIRLESS RAT; IN VITRO STUDY; IONTOPHORESIS; NONHUMAN; PH; PRIORITY JOURNAL; RAT; SKIN PERMEABILITY;

EID: 61649111988     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.1080/10837450802409479     Document Type: Article

References (32)

1. De Cicco M, Bortolussi R, Fantin D, et al. Supportive therapy of elderly cancer patients. Crit. Rev. Oncol. Hematol. 2002;42:189-211.
2. Ashburn MA, Ogden LL, Zhang J, Love G, Basta SV. The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat. J. Pain. 2003;4:291-297.
3. Bossart J, Jouhikainen T. Addressing the analgesic gap in breakthrough cancer pain - a drug delivery case study. Drug Deliv. Tech. 2008;8:38-42.
4. Banga AK, Bose S, Ghosh TK. Iontophoresis and electroporation: comparisons and contrasts. Int. J. Pharm. 1999;179:1-19.
5. Salvato C, Aretini G, Serraglia D, et al. Opioid prescription for terminally ill outpatients in a district of northern Italy: a retrospective survey. Pharmacol Res. 2003;48:75-82.
6. Quigley C, Wiffen P. A systemic review of hydromorphone in acute and chronic pain. J. Pain Symptom. Manage. 2003;25:169-178.
7. Kumar MG, Lin S. Hydromorphone in the management of cancer-related pain: an update on routes of administration and dosage forms. J. Pharm. Pharm. Sci. 2007;10:504-518.
8. Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. Adv. Drug Deliv. Rev. 2004;56:619-658.
9. Padmanabhan RV, Phipps JB, Lattin GA, Sawchuk RJ. In vitro and in vivo evaluation of transdermal iontophoretic delivery of hydromorphone. J. Control. Rel. 1990;11:123-135.
10. Schuetz YB, Naik A, Guy RH, Kalia YN. Effect of amino acid sequence on transdermal iontophoretic peptide delivery. Eur. J. Pharm. Sci. 2005;26:429-437.
11. Mudry B, Guy RH, Delgado-Charro MB. Transport numbers in transdermal iontophoresis. Biophys. J. 2006;90:2822-2830.
12. Banga AK. Electrically assisted transdermal delivery of drugs. In: Wise DL, ed. Handbook of Pharmaceutical Controlled Release Technology. New York: Marcel Dekker; 2000:567-581.
13. Friend DR. In vitro skin permeation techniques. J. Control. Rel. 1992;18:235-248.
14. Cullander C. What are the pathways of iontophoretic current flow through mammaliam skin? Adv. Drug Deliv. Rev. 1992;9:119-135.
15. Marro D, Guy RH, Delgado-Charro MB. Characterization of the iontophoretic permselectivity properties of human and pig skin. J. Control. Rel. 2001;70:213-217.
16. Medi BM, Singh J. Electronically facilitated transdermal delivery of human parathyroid hormone (1-34). Int. J. Pharm. 2003;263:25-33.
17. Prausnitz MR, Lee CS, Liu CH, et al. Transdermal transport efficiency during skin electroporation and iontophoresis. J. Control. Rel. 1996;38:205-217.
18. Kalia YN, Guy RH. Interaction between penetration enhancers and iontophoresis: effect on human skin impedance in vivo. J. Control. Rel. 1997;44:33-42.
19. Nugroho AK, Li L, Dijkstra D, Wikstrom A, Danhof M, Bouwstra JA. Transdermal iontophoresis of the dopamine agonist 5-OH-DPAT in human skin in vitro. J. Control. Rel. 2005;103:393-403.
20. Nair VB, Panchagnula R. Influence of electrical parameters in the iontophoretic delivery of a small peptide: In vitro studies using arginine-vasopressin as a model peptide. Il Farmaco. 2004;59:583-593.
21. Nair VB, Panchagnula R. Physicochemical considerations in the iontophoretic delivery of a small peptide: In vitro studies using arginine-vasopressin as a model peptide. Pharmacol. Res. 2003;48:175-182.
22. Li SK, Zhang Y, Zhu H, Higuchi WI, White HS. Influence of asymmetric donor-receiver ion concentration upon transscleral iontophoretic transport. J. Pharm. Sci. 2005;94: 847-860.
23. Roy SD, Flynn GL. Transdermal delivery of narcotic analgesics: Comparative permeabilities of narcotic analgesics through human cadaver skin. Pharm. Res. 1989;6:825-832.
24. Marro D, Kalia YN, Delgado-Charro MB, Guy RH. Contributions of electromigration and electroosmosis to iontophoretic drug delivery. Pharm. Res. 2001;18:1701-1708.
25. Tamada JA, Comyns K. Effect of formulation factors on electroosmotic glucose transport through human skin in vivo. J. Pharm. Sci. 2005;94:1839-1849.
26. Li SK, Zhu H, Higuchi WI. Enhanced transscleral iontophoretic transport with ion-exchange membrane. Pharm. Res. 2006;23:1857-1867.
27. Hirvonen J, Guy RH. Iontophoretic delivery across the skin: electroosmosis and its modulation by drug substances. Pharm. Res. 1997;14:1258-1263.
28. Luzardo-Alvarez A, Delgado-Charro MB, Blanco-Mendez J. Iontophoretic delivery of ropinirole hydrochloride: Effect of current density and vehicle formulation. Pharm. Res. 2001;18:1714-1720.
29. Meidan VM, Al-Khalili M, Michniak B. Enhanced iontophoretic delivery of buspirone hydrochloride across human skin using chemical enhancers. Int. J. Pharm. 2003;264: 73-83.
30. Tang H, Blankschtein D, Langer R. Prediction of steady-state skin permeabilities of polar and nonpolar permeants across excised pig skin based on measurements of transient diffusion: Characterization of hydration effects on the skin porous pathway. J. Pharm. Sci. 2002;91:1891-1907.
31. Upasani RS, Banga AK. Response surface methodology to investigate the iontophoretic delivery of tacrine hydrochloride. Pharm. Res. 2004;21:2293-2299.
32. Sarhill N, Walsh D, Nelson KA. Hydromorphone: Pharmacology and clinical applications in cancer patients. Support Care Cancer. 2001;9:84-96.